PURPOSE: Lynch syndrome is an autosomal dominant syndrome of familial malignancies resulting from germ line mutations in DNA mismatch repair (MMR) genes. Our goal was to take a pathway-based approach to investigate the influence of polymorphisms in cell cycle-related genes on age of onset for Lynch syndrome using a tree model. EXPERIMENTAL DESIGN: We evaluated polymorphisms in a panel of cell cycle-related genes (AURKA, CDKN2A, TP53, E2F2, CCND1, TP73, MDM2, IGF1, and CDKN2B) in 220 MMR gene mutation carriers from 129 families. We applied a novel statistical approach, tree modeling (Classification and Regression Tree), to the analysis of data on patients with Lynch syndrome to identify individuals with a higher probability of developing colorectal cancer at an early age and explore the gene-gene interactions between polymorphisms in cell cycle genes. RESULTS: We found that the subgroup with CDKN2A C580T wild-type genotype, IGF1 CA-repeats >or=19, E2F2 variant genotype, AURKA wild-type genotype, and CCND1 variant genotype had the youngest age of onset, with a 45-year median onset age, while the subgroup with CDKN2A C580T wild-type genotype, IGF1 CA-repeats >or=19, E2F2 wild-type genotype, and AURKA variant genotype had the latest median age of onset, which was 70 years. Furthermore, we found evidence of a possible gene-gene interaction between E2F2 and AURKA genes related to CRC age of onset. CONCLUSIONS: Polymorphisms in these cell cycle-related genes work together to modify the age at the onset of CRC in patients with Lynch syndrome. These studies provide an important part of the foundation for development of a model for stratifying age of onset risk among those with Lynch syndrome.
PURPOSE:Lynch syndrome is an autosomal dominant syndrome of familial malignancies resulting from germ line mutations in DNA mismatch repair (MMR) genes. Our goal was to take a pathway-based approach to investigate the influence of polymorphisms in cell cycle-related genes on age of onset for Lynch syndrome using a tree model. EXPERIMENTAL DESIGN: We evaluated polymorphisms in a panel of cell cycle-related genes (AURKA, CDKN2A, TP53, E2F2, CCND1, TP73, MDM2, IGF1, and CDKN2B) in 220 MMR gene mutation carriers from 129 families. We applied a novel statistical approach, tree modeling (Classification and Regression Tree), to the analysis of data on patients with Lynch syndrome to identify individuals with a higher probability of developing colorectal cancer at an early age and explore the gene-gene interactions between polymorphisms in cell cycle genes. RESULTS: We found that the subgroup with CDKN2A C580T wild-type genotype, IGF1 CA-repeats >or=19, E2F2 variant genotype, AURKA wild-type genotype, and CCND1 variant genotype had the youngest age of onset, with a 45-year median onset age, while the subgroup with CDKN2A C580T wild-type genotype, IGF1 CA-repeats >or=19, E2F2 wild-type genotype, and AURKA variant genotype had the latest median age of onset, which was 70 years. Furthermore, we found evidence of a possible gene-gene interaction between E2F2 and AURKA genes related to CRC age of onset. CONCLUSIONS: Polymorphisms in these cell cycle-related genes work together to modify the age at the onset of CRC in patients with Lynch syndrome. These studies provide an important part of the foundation for development of a model for stratifying age of onset risk among those with Lynch syndrome.
Authors: Wei Wang; Margaret R Spitz; Hushan Yang; Charles Lu; David J Stewart; Xifeng Wu Journal: Clin Cancer Res Date: 2007-10-01 Impact factor: 12.531
Authors: Stefan Krüger; Christoph Engel; Andrea Bier; Elisabeth Mangold; Constanze Pagenstecher; Magnus von Knebel Doeberitz; Elke Holinski-Feder; Gabriela Moeslein; Gisela Keller; Erdmute Kunstmann; Waltraut Friedl; Jens Plaschke; Josef Rüschoff; Hans K Schackert Journal: Cancer Lett Date: 2006-05-18 Impact factor: 8.679
Authors: Bente A Talseth; Cliff Meldrum; Janina Suchy; Grzegroz Kurzawski; Jan Lubinski; Rodney J Scott Journal: Int J Cancer Date: 2006-05-15 Impact factor: 7.396
Authors: Mariëlle W G Ruijs; Marjanka K Schmidt; Heli Nevanlinna; Johanna Tommiska; Kristiina Aittomäki; Roelof Pruntel; Senno Verhoef; Laura J Van't Veer Journal: Eur J Hum Genet Date: 2006-09-27 Impact factor: 4.246
Authors: Noralane M Lindor; Gloria M Petersen; Donald W Hadley; Anita Y Kinney; Susan Miesfeldt; Karen H Lu; Patrick Lynch; Wylie Burke; Nancy Press Journal: JAMA Date: 2006-09-27 Impact factor: 56.272
Authors: Henry T Lynch; C Richard Boland; Gordon Gong; Trudy G Shaw; Patrick M Lynch; Riccardo Fodde; Jane F Lynch; Albert de la Chapelle Journal: Eur J Hum Genet Date: 2006-04 Impact factor: 4.246
Authors: Mohd Nizam Zahary; Abdul Aziz Ahmad Aizat; Gurjeet Kaur; Lee Yeong Yeh; Maya Mazuwin; Ravindran Ankathil Journal: Oncol Lett Date: 2015-09-18 Impact factor: 2.967
Authors: Amanda S Bruegl; Bojana Djordjevic; Brittany Batte; Molly Daniels; Bryan Fellman; Diana Urbauer; Rajyalakshmi Luthra; Charlotte Sun; Karen H Lu; Russell R Broaddus Journal: Cancer Prev Res (Phila) Date: 2014-04-25
Authors: Karolina Gołąbek; Krzysztof Biernacki; Jadwiga Gaździcka; Joanna K Strzelczyk; Katarzyna Miśkiewicz-Orczyk; Łukasz Krakowczyk; Natalia Zięba; Paweł Kiczmer; Zofia Ostrowska; Maciej Misiołek Journal: Biomed Res Int Date: 2021-03-30 Impact factor: 3.411